title: [Technological approaches to development of whole-virion inactivated vaccine from recombinant strain against A/H5N1 influenza in the Republic of Kazakhstan].
abstract: OBJECTIVE
  Development of technological stages of preparation of experimental influenza whole-virion inactivated adsorbed vaccine based on recombinant influenza virus strains NIBRG-14 and A/Astana/RG/6:2/2009.
  
  
  METHODS
  2 recombinant vaccines influenza strains were used in the study--NIBRG-14 and A/Astana/RG/6:2/2009. Purification of native virus-containing allantoic fluid was performed by ion-exchange chromatography. The virus was inactivated by formaldehyde. Merthiolate at concentration of 0.1 mg/ml was added to the vaccine as a preserving substance. Aluminium hydroxide was used as an adjuvant. Harmlessness and immunogenicity (HI) of the constructed preparation are determining.
  
  
  RESULTS
  Virus-containing materials from recombinant strains with biological activity of 8.5 - 9.0 lg EID50/cm3 and hemagglutination activity of 1:256 - 1:1024 in chicken embryos were obtained. Optimal inactivation regimen of non-purified suspensions by formaldehyde was established and combined scheme of purification and concentration of influenza virus was selected that provide harmlessness and immunogenicity of experimental samples of inactivated vaccines against highly pathogenic influenza A/H5N1 in experiments in mice.
  
  
  CONCLUSIONS
  The data obtained on quality parameters of intermediate products and final vaccine give evidence on their compliance with normative parameters for whole-virion influenza purified vaccine.
authors.forename: Zh K
authors.initials: ZhK
authors.lastname: Kydyrbaev
authors.forename: S M
authors.initials: SM
authors.lastname: Mamadaliev
authors.forename: N N
authors.initials: NN
authors.lastname: Asanzhanova
authors.forename: K K
authors.initials: KK
authors.lastname: Tabynov
authors.forename: Sh Zh
authors.initials: ShZh
authors.lastname: Ryskel'dinova
authors.forename: O V
authors.initials: OV
authors.lastname: Cherviakova
authors.forename: N T
authors.initials: NT
authors.lastname: Sandybaev
authors.forename: B M
authors.initials: BM
authors.lastname: Khaĭrullin
authors.forename: O I
authors.initials: OI
authors.lastname: Kiselev
mesh_terms: D000276:Adjuvants, Immunologic; D000536:Aluminum Hydroxide / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D002642:Chick Embryo; D005557:Formaldehyde / Q000737:chemistry; D006384:Hemagglutination; D006801:Humans; D007114:Immunization; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000096:biosynthesis / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D007623:Kazakhstan; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; D014771:Virion / Q000276:immunology / Q000302:isolation & purification
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; D005557:Formaldehyde; D000536:Aluminum Hydroxide